We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 66.26+2.9%4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen8/8/2006 11:19:30 AM
   of 347
GenoMed's West Nile Virus Trial Endorsed by Emergency Medicine Authority

Neal Handly, MD
tel. 610.563.0664

David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9933

ST. LOUIS—August 8, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, today announced the endorsement of its trial for West Nile virus encephalitis by an authority in Emergency Medicine, Dr. Neal Handly.

Dr. Handly is Associate Director of Research for the Department of Emergency Medicine at Drexel University College of Medicine and a Fellow of the American Academy of Emergency Medicine. Dr. Handly chairs the Academy's Subcommittee on Information Technology.

Dr. Handly said, "GenoMed's protocol is extremely exciting, since we're in the grip of another West Nile epidemic this summer without any known treatment. The Emergency Room is where these cases are seen first. It makes sense to have the ER be a partner in a clinical trial."

Dr. Handly continued, "Dr. Moskowitz uses safe medicines already familiar to every ER physician. What makes his approach appealing is the possibility that it may work for many viruses, including avian influenza and bioterrorist viral attacks. These last two scenarios are of special concern to the Emergency Medicine community."

About Dr. Handly

Dr. Neal Handly is an Assistant Professor in the Department of Emergency Medicine at Drexel University College of Medicine in Philadelphia, PA. He was consulted to create a state-of-the-art ER this summer in Beirut, Lebanon but has been prevented from doing so by the current hostilities.

About GenoMed

Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 86% treatment success rate (19 of 22 patients). This summer the Company extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website,, by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext